TMC-353121 | TMC353121 | CAS#857066-90-1 | RSV fusion inhibitor

MedKoo Cat#: 526819 | Name: TMC353121

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TMC353121 is a a respiratory syncytial virus (RSV) fusion inhibitor as a candidate to treat human respiratory syncytial virus infection. TMC353121 exerted dose-dependent antiviral effect ranging from full inhibition to absence of antiviral activity, in a preclinical model highly permissive for RSV replication. Human respiratory syncytial virus (hRSV) is a significant cause of respiratory illness in at-risk pediatric patients, immunocompromised adults and the elderly.

Chemical Structure

TMC353121

CAS#857066-90-1

Theoretical Analysis

MedKoo Cat#: 526819

Name: TMC353121

CAS#: 857066-90-1

Chemical Formula: C32H42N6O3

Exact Mass: 558.3318

Molecular Weight: 558.73

Elemental Analysis: C, 68.79; H, 7.58; N, 15.04; O, 8.59

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

TMC-353121; TMC 353121; TMC353121.

IUPAC/Chemical Name

2-((6-(((2-(3-hydroxypropyl)-5-methylphenyl)amino)methyl)-2-((3-morpholinopropyl)amino)-1H-benzo[d]imidazol-1-yl)methyl)-6-methylpyridin-3-ol

InChi Key

InChi Code

SMILES Code

OC1=CC=C(C)N=C1CN2C(NCCCN3CCOCC3)=NC4=CC=C(CNC5=CC(C)=CC=C5CCCO)C=C24

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 558.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ispas G, Koul A, Verbeeck J, Sheehan J, Sanders-Beer B, Roymans D, Andries K, Rouan MC, De Jonghe S, Bonfanti JF, Vanstockem M, Simmen K, Verloes R. Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model. PLoS One. 2015 May 26;10(5):e0126959. doi: 10.1371/journal.pone.0126959. eCollection 2015. PubMed PMID: 26010881; PubMed Central PMCID: PMC4444337. 2: Hegele RG. Respiratory syncytial virus therapy and prophylaxis: have we finally turned the corner? Eur Respir J. 2011 Aug;38(2):246-7. doi: 10.1183/09031936.00012011. PubMed PMID: 21804160. 3: Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, Van Kerckhove B, Roymans D, De Meulder M, Rouan MC, Van Remoortere P, Bonfanti JF, Van Velsen F, Koul A, Vanstockem M, Andries K, Sowinski P, Wang B, Openshaw P, Verloes R. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. 2011 Aug;38(2):401-8. doi: 10.1183/09031936.00005610. Epub 2010 Dec 9. PubMed PMID: 21148224. 4: Rouan MC, Gevers T, Roymans D, de Zwart L, Nauwelaers D, De Meulder M, van Remoortere P, Vanstockem M, Koul A, Simmen K, Andries K. Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. Antimicrob Agents Chemother. 2010 Nov;54(11):4534-9. doi: 10.1128/AAC.00643-10. Epub 2010 Sep 7. PubMed PMID: 20823290; PubMed Central PMCID: PMC2976145. 5: Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, Verheyen N, Kim H, Willebrords R, Bonfanti JF, Bruinzeel W, Cummings MD, van Vlijmen H, Andries K. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):308-13. doi: 10.1073/pnas.0910108106. Epub 2009 Dec 4. PubMed PMID: 19966279; PubMed Central PMCID: PMC2806771. 6: Bonfanti JF, Roymans D. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87. Review. PubMed PMID: 19562644. 7: Bonfanti JF, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, van Remoortere P, Janssens F, Wigerinck P, Andries K. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem. 2008 Feb 28;51(4):875-96. doi: 10.1021/jm701284j. Epub 2008 Feb 7. PubMed PMID: 18254606.